Bioartificial organs may help reduce risk of zoonosis in xenotransplantation

Artificial Organs

Volumn 23, Issue 4, 1999, Pages 366-367

  Mullon, Claudy ^a  

^a Circe Biomedical Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOARTIFICIAL ORGANS; XENOTRANSPLANTATION;

ARTIFICIAL ORGANS;

ARTICLE; ARTIFICIAL LIVER; ARTIFICIAL ORGAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; HUMAN; HUMAN CELL; INFECTION CONTROL; LIVER FAILURE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RETROVIRUS; XENOTRANSPLANTATION; ZOONOSIS;

UNIDENTIFIED RETROVIRUS;

EID: 0032926289     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1999.06353.x     Document Type: Article

References (16)

1. Edge AS, Gosse ME, Dinsmore J. Xenogeneic cell therapy: Current progress and future development in porcine cell transplantation. Cell Transplant 1998;7(6):525-39.
2. Lin S, Saadi S. New development in solid organ xenotransplantation. Graft 1998;1(2):45-7.
3. Chari RS, Collins BH, Magee JC, Dimaio JM, Kirk AD, Harland RC, McCann RL, Platt JL, Meyers WC. Treatment of hepatic failure with ex vivo pig liver perfusion followed by liver transplantation. N Engl J Med 1994;331:234-7.
4. Patience C, Patton GS, Takeuchi Y, Weiss RA, McClure MO, Rydberg L, Breiner ME. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 1998;352:699-701.
5. Bach F, Finenerg HV. Call for moratorium on xenotransplants. Nature 1998;391:326.
6. Vogel G. No moratorium on clinical trials. Science 1998;279: 648.
7. Patience C, Takeuchi Y, Weiss R. Infection of human cells by an endogenous virus of pigs. Nat Med 1997;3:282-6.
8. Martin U, Kiessig V, Blusch JH, Haverich A, von der Helm K, Herden T, Steinhoff G. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 1998;252:692-4.
9. Heneine W, Tibell A, Switzer W, Sandstrom P, Rosales GV, Mathews A, Korsgren O, Chapman LE, Folks TM, Groth CG. No evidence of infection with porcine endogenous retrovirus on recipients of porcine islet-cell xenografts. Lancet 1998;352: 695-9.
10. McLaughlin BE, Tosone CM, Custer LM, Mullon C. Overview of extracorporeal liver support systems and clinical results. Ann NY Acad Sci (in press).
11. Humes HD. Tissue engineering of a bioartificial kidney: A universal donor organ. Transplant Proc 1996;28(4):2032-5.
12. Maki T, Otsu I, O'Neil J, Dunleavy K, Mullon C, Solomon B, Monaco A. Treatment of diabetes by xenogeneic islets without immunosuppression: Use of a vascularized bioartificial pancreas. Diabetes 1996;45:342-7.
13. Watanabe FD, Mullon C, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Solomon B, Demetriou AA. Clinical experience with a bioartificial liver (BAL) in the treatment of severe liver failure: A phase I clinical trial. Ann Surg 1997;225(5):484-94.
14. Hewitt W, Rozga J, Mullon C, Demetriou A. Bioartificial liver: Experimental and clinical experience. In: Franco D, Boudjema K, Varet B, eds. Ilots de Langerhans et hépatocytes: Vers une utilisation thérapeutique. Les Editions Paris: INSERM, 1998:105-18.
15. Chen SC, Mullon C, Kahakue E, Watanabe F, Hewitt W, Eguchi S, Middleton Y, Arkadopoulos N, Rozga J, Solomon B, Demetriou A. Treatment of severe liver failure with a bioartificial liver. Ann NY Acad Sci 1997;831:350-60.
16. Infectious diseases issues in xenotransplantation - draft guidelines. U.S. Federal Register. 1996, Volume 61, Number 185.